Researchers from the Weizmann Institute of Science (WIS) Israel, together with researchers from the United States, created an innovative antibody-based drug therapy that enhances the human immune response against cancerous cells. The treatment mainly aims at the tumor microenvironment, particularly in a serious triple-negative breast cancer form of this disease.
The study shows that the immune cells are stimulated to produce "molecular bridges" in the case of triple-negative breast cancer through the protein called CD84. Such bridges inhibit the attacking capabilities of the immune cells toward the tumor and lead to immunosuppression. Through experiments researchers blocked these bridges with the help of an antibody. They were able to restore the immunity potential against the tumor cells, where they halted the progression of the tumors in mouse models.
Key Findings and Medication Treatment
This type of breast cancer has documented research evidence showing that its carcinoma cells have low expression of CD84, but stimulate the surrounding immune cells to express huge amounts of this protein. Genetic modification of mice deficient in CD84 showed smaller size of the tumor and underlined the role of CD84 in cell activity. This antibody was given to mice on a twice-weekly basis and the study demonstrated that it strongly delayed the growth of the tumors in some mice and even complete recoveries were reported.
Inputs by Agencies
Image Source: Multiple Agencies
Ⓒ Copyright 2024. All Rights Reserved Powered by Vygr Media.
